These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36463731)

  • 21. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel.
    Sun M; Xu B; Chen C; Zhu Y; Li X; Chen K
    Clin Epigenetics; 2024 Feb; 16(1):25. PubMed ID: 38336771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features.
    Nguyen L; Van Hoeck A; Cuppen E
    Nat Commun; 2022 Jul; 13(1):4013. PubMed ID: 35817764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deep Learning-Based Identification of Tissue of Origin for Carcinomas of Unknown Primary Using MicroRNA Expression: Algorithm Development and Validation.
    Raghu A; Raghu A; Wise JF
    JMIR Bioinform Biotechnol; 2024 Jul; 5():e56538. PubMed ID: 39046787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary.
    Kolbinger FR; Bernard V; Lee JJ; Stephens BM; Branchi V; Raghav KPS; Maitra A; Guerrero PA; Semaan A
    J Gastrointest Cancer; 2023 Dec; 54(4):1276-1285. PubMed ID: 36862364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic and therapeutic management of cancer of an unknown primary.
    Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
    Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.
    Michuda J; Breschi A; Kapilivsky J; Manghnani K; McCarter C; Hockenberry AJ; Mineo B; Igartua C; Dudley JT; Stumpe MC; Beaubier N; Shirazi M; Jones R; Morency E; Blackwell K; Guinney J; Beauchamp KA; Taxter T
    Mol Diagn Ther; 2023 Jul; 27(4):499-511. PubMed ID: 37099070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
    Li M; Li H; Hong G; Tang Z; Liu G; Lin X; Lin M; Qi L; Guo Z
    BMC Cancer; 2019 Jan; 19(1):67. PubMed ID: 30642283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
    Samsom KG; Bosch LJW; Schipper LJ; Schout D; Roepman P; Boelens MC; Lalezari F; Klompenhouwer EG; de Langen AJ; Buffart TE; van Linder BMH; van Deventer K; van den Burg K; Unmehopa U; Rosenberg EH; Koster R; Hogervorst FBL; van den Berg JG; Riethorst I; Schoenmaker L; van Beek D; de Bruijn E; van der Hoeven JJM; van Snellenberg H; van der Kolk LE; Cuppen E; Voest EE; Meijer GA; Monkhorst K
    Nat Protoc; 2024 Mar; 19(3):700-726. PubMed ID: 38092944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
    Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
    Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.
    Staub E; Buhr HJ; Gröne J
    Oncogene; 2010 Aug; 29(31):4485-92. PubMed ID: 20514016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
    Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
    ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and management of metastatic neoplasms with unknown primary.
    Bochtler T; Löffler H; Krämer A
    Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer of Unknown Primary in the Molecular Era.
    Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
    Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
    Pauli C; Bochtler T; Mileshkin L; Baciarello G; Losa F; Ross JS; Pentheroudakis G; Zarkavelis G; Yalcin S; Özgüroğlu M; Beringer A; Scarato J; Mueller-Ohldach M; Thomas M; Moch H; Krämer A
    Oncologist; 2021 May; 26(5):e769-e779. PubMed ID: 33687747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
    Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
    Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.